Potential Roles for First-Line Targeted Therapy for Advanced Melanoma

Panelists discuss how first-line targeted therapy for advanced melanoma, particularly BRAF and MEK inhibitors, may offer significant benefits in patients with BRAF-mutant tumors, emphasizing rapid response and the potential for combination with immunotherapy to improve long-term outcomes.

EP: 1.Treatment Decisions in Metastatic Melanoma: Immunotherapy vs Targeted Therapy

EP: 2.Key Takeaways from the RELATIVITY-047 Trial: Managing Advanced Melanoma

EP: 3.Indirect Treatment Comparison: RELATIVITY-047 and CheckMate 067

EP: 4.Dual Immunotherapy IO Treatment and Sequencing Decisions for Melanoma

EP: 5.Insight on Treating Patients With Melanoma With Brain Metastases

EP: 6.Expert Insight on Using Dual-IO Regimens for Melanoma in Real-World Practice

Now Viewing

EP: 7.Potential Roles for First-Line Targeted Therapy for Advanced Melanoma

Recent Videos